Caroline Seymour | Authors


Nivolumab/Ipilimumab Triplet Improves OS in Advanced NSCLC Compared With Chemotherapy Alone

June 21, 2021

A frontline regimen nivolumab, ipilimumab, and 2 cycles of chemotherapy yielded an improvement in overall survival versus chemotherapy alone in patients with advanced non–small cell lung cancer. The benefit was observed regardless of tumor mutational burden status in the tissue or blood.